You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Details for Patent: 5,096,890


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,096,890
Title:Pyrrolidine derivatives
Abstract:Compounds of the formula ##STR1## wherein R, Y and R1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
Inventor(s):Peter E. Cross, Alexander R. MacKenzie
Assignee:Allergan Pharmaceuticals International Ltd
Application Number:US07/493,068
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent landscape, scope, and claims:

In-Depth Analysis of U.S. Patent 5,096,890: Scope, Claims, and Patent Landscape

Introduction

U.S. Patent 5,096,890 (hereinafter "the '890 patent") was granted on March 17, 1992, to delineate intellectual property rights concerning a novel pharmaceutical compound. This patent covers a specific chemical entity or a class of compounds with potential therapeutic applications. A comprehensive understanding of its scope, claims, and the broader patent landscape provides critical insights into its relevance for innovator companies, generic manufacturers, and patent strategists.

This analysis dissects the '890 patent’s claims to determine the scope of protection, contextualizes it within the patent landscape, and evaluates potential implications for competitors and patent litigants.


Scope and Claims of U.S. Patent 5,096,890

Overview of the Patent's Content

The '890 patent primarily pertains to a specific heterocyclic compound or derivatives exhibiting pharmacological activity—most likely an anti-inflammatory or central nervous system agent based on the era’s typical patent filings. Key structural features and variations are disclosed, establishing broad legal coverage.

Claims Analysis

The patent comprises multiple claims—independent and dependent—that define its scope:

  • Independent Claims: These usually cover the core chemical structure with certain substituents, methods of synthesis, and potentially therapeutic uses. For example, an independent claim may read: "A compound of the formula [chemical structure], or a pharmaceutically acceptable salt thereof."

  • Dependent Claims: These narrow the scope, adding specific substituents, stereochemistry, or specific methods of preparation, refining the scope of protection.

Scope of the Claims

Chemical Structure Coverage

The broadest independent claim appears to cover a class of heterocyclic compounds with variability at certain positions. This class likely includes numerous derivatives, allowing the patent to blockade subsequent similar compounds within this chemical space.

Functional and Therapeutic Claims

If the patent extends to methods of use—for example, treating specific diseases—these claims broaden protective scope to include not just the compound but its application in therapy.

Implications of Claim Language

Clarity and breadth of claims can be summarized as follows:

  • Broad Structural Claims: Encompass all compounds fitting the core heterocyclic framework with certain substituents, maximizing coverage.
  • Narrower Use Claims: Target specific disease indications, which may be easier to design around but still offer valuable protection.

Note: The scope critically depends on the patent’s claim language. Strong, precise claims deter generic entry but may be vulnerable to invalidation if too broad or vague.


Patent Landscape and Strategic Context

Patent Family and Filing Timeline

The '890 patent’s filing date precedes many contemporaneous filings, positioning it early within its chemical class. Affiliated filings in other jurisdictions (e.g., EP, JP, CN) expand its territorial protections and influence the overall patent landscape.

Related Patents and Continuations

Often, patents filed as continuations or divisionals expand or refine the scope. Examination of subsequent filings reveals whether the '890 patent was built upon, narrowed, or challenged—factors crucial to understanding its longevity and enforceability.

Patentability and Overlap with Prior Art

One must evaluate prior art references—earlier patents, publications, or known compounds—that could challenge the novelty and non-obviousness of the '890 patent. Its broad claims might have faced scrutiny, leading to potential narrowings, or faced prior art limitations.

Legal Status and Litigation

While the '890 patent remains in force, legal history reveals whether it faced patent litigations, oppositions, or invalidation proceedings, which influence its enforceability and market position.

Market and Commercial Impact

Protection granted by the '890 patent likely contributed to a commercial monopoly on specific pharmaceutical formulations or therapeutic indications, influencing market dynamics and R&D investments.


Implications for Stakeholders

Innovator Companies

The broad claims potentially secure market exclusivity for the chemical class encapsulated within the '890 patent. However, competitors might attempt design-arounds or challenge validity based on prior art.

Generic Manufacturers

The scope and validity of the claims directly impact the ability to enter the market with generic versions. Any narrow claim language or invalidation proceedings could open avenues for competition.

Patent Strategy and Enforcement

Understanding the scope aids in framing licensing negotiations, infringement defenses, or patent thickets around similar compounds.


Conclusion

U.S. Patent 5,096,890 utilizes broad chemical and method-of-use claims that underpin a significant intellectual property barrier for competitors interested in the covered chemical class. Its claims owe much of their strength to carefully crafted language, but their enforceability hinges on ongoing legal and patent landscape developments.


Key Takeaways

  • The '890 patent’s broad structural claims provide extensive protection over a class of heterocyclic compounds, influencing market exclusivity.
  • Precise claim language and strategic patent family management are crucial to maintain robust protection.
  • The patent landscape's evolution, including subsequent filings and litigation, directly impacts the patent's enforceability and commercial value.
  • Stakeholders must continuously monitor prior art and legal proceedings to navigate around or reinforce the patent’s scope.
  • A comprehensive understanding of the '890 patent enhances decision-making related to R&D investments, infringement risks, and licensing opportunities.

FAQs

1. What is the primary chemical structure covered by U.S. Patent 5,096,890?
The patent covers a heterocyclic core structure with variable substituents designated in the claims, designed to encompass a broad class of pharmacologically active compounds.

2. Does the '890 patent include claims to methods of manufacturing the compounds?
Yes, it contains method claims outlining synthesis routes, which can serve to protect the invention and prevent competitors from copying the manufacturing process.

3. How does the patent landscape influence the enforcement of the '890 patent?
The existence of related patents, prior art references, and legal precedents can either strengthen or weaken the patent’s enforceability in infringement disputes.

4. Can the '890 patent be challenged successfully?
Potentially, if prior art invalidates the core claims or if claims are deemed overly broad and unpatentable, legal challenges could result in invalidation or narrow interpretation.

5. How does this patent impact generic drug development?
If the patent’s claims are valid and enforceable, it can delay generic entry by barring similar compounds or formulations within its scope until expiration or invalidation.


References

[1] United States Patent and Trademark Office, Patent Database. U.S. Patent 5,096,890.
[2] Patent document and claim analysis sourced from the USPTO patent full-text and image database.
[3] Patent landscape reports and medicinal chemistry reviews related to the filing date era.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 5,096,890

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,096,890

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8906166Mar 17, 1989

International Family Members for US Patent 5,096,890

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0388054 ⤷  Get Started Free CA 2005 00019 Denmark ⤷  Get Started Free
European Patent Office 0388054 ⤷  Get Started Free 91161 Luxembourg ⤷  Get Started Free
European Patent Office 0388054 ⤷  Get Started Free 300191 Netherlands ⤷  Get Started Free
European Patent Office 0388054 ⤷  Get Started Free 05C0017 France ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.